PDF herunterladen
Thromb Haemost 2022; 122(03): 336-343
DOI: 10.1055/a-1508-7919
Coagulation and Fibrinolysis

Demonstration of Three Distinct High-Molecular-Weight Complexes between Plasminogen Activator Inhibitor Type 1 and Tissue-Type Plasminogen Activator

Tae Ito
1   Department of Medical Physiology, Hamamatsu University School of Medicine, Hamamatsu, Japan
,
Yuko Suzuki
1   Department of Medical Physiology, Hamamatsu University School of Medicine, Hamamatsu, Japan
,
Hideto Sano
1   Department of Medical Physiology, Hamamatsu University School of Medicine, Hamamatsu, Japan
,
Naoki Honkura
1   Department of Medical Physiology, Hamamatsu University School of Medicine, Hamamatsu, Japan
,
Francis J. Castellino
2   W.M. Keck Center for Transgene Research, University of Notre Dame, Dame, Indiana, United States
,
Tetsumei Urano
1   Department of Medical Physiology, Hamamatsu University School of Medicine, Hamamatsu, Japan
3   Shizuoka Graduate University of Public Health, Shizuoka, Japan
› Institutsangaben Funding This work was supported by JSPS KAKENHI (Grant Number JP19K08577 to Y.S. and C:24590273 to T.U.), Japan Agency for Medical Research and Development (AMED) (21ek0210154h0002 to T.U.), and by a grant from the Smoking Research Foundation to T.U.
› Weitere Informationen
Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Background Details of the molecular interaction between tissue-type plasminogen activator (tPA) and plasminogen activator inhibitor type-1 (PAI-1) remain unknown.

Methods and Results Three distinct forms of high-molecular-weight complexes are demonstrated. Two of the forms were detected by mass spectrometry. The high molecular mass detected by MALDI-TOF MS (matrix-assisted laser desorption ionization-time of flight mass spectrometry) was 107,029 Da, which corresponds to the sum of molecular masses of the intact tPA (65,320 Da) and the intact PAI-1 (42,416 Da). The lower molecular mass was 104,367 Da and is proposed to lack the C-terminal bait peptide of PAI-1 (calculated mass: 3,804 Da), which was detected as a 3,808 Da fragment. When the complex was analyzed by SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis), only a single band was observed. However, after treatment by SDS and Triton X-100, two distinct forms of the complex with different mobilities were shown by SDS-PAGE. The higher molecular weight band demonstrated specific tPA activity on fibrin autography, whereas the lower molecular weight band did not. Peptide sequence analysis of these two bands, however, unexpectedly revealed the existence of the C-terminal cleavage peptide in both bands and its amount was less in the upper band. In the upper band, the sequences corresponding to the regions at the interface between two molecules in its Michaelis intermediate were diminished. Thus, these two bands corresponded to distinct nonacyl–enzyme complexes, wherein only the upper band liberated free tPA under the conditions employed.

Conclusion These data suggest that under physiological conditions a fraction of the tPA–PAI-1 population exists as nonacylated–enzyme inhibitor complex.

Keywords

tissue-type plasminogen activator (tPA) - plasminogen activator inhibitor type 1 (PAI-1) - SERPIN - serine protease - fibrinolysis

Author Contributions

T.I. and Y.S. designed the study, performed the experiments, analyzed and interpreted the data, and wrote the paper; H.S. and N.H. discussed the results; F.J.C. and T.U. designed and conceptualized the study and wrote the paper. All authors read and approved the paper.




Publikationsverlauf

Eingereicht: 25. Februar 2021

Angenommen: 11. Mai 2021

Accepted Manuscript online:
13. Mai 2021

Artikel online veröffentlicht:
18. Juni 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Fay WP. Plasminogen activator inhibitor 1, fibrin, and the vascular response to injury. Trends Cardiovasc Med 2004; 14 (05) 196-202
    CrossrefPubMedGoogle Scholar
  • 2 Iwaki T, Urano T, Umemura K. PAI-1, progress in understanding the clinical problem and its aetiology. Br J Haematol 2012; 157 (03) 291-298
    CrossrefPubMedGoogle Scholar
  • 3 Urano T, Castellino FJ, Suzuki Y. Regulation of plasminogen activation on cell surfaces and fibrin. J Thromb Haemost 2018; 16 (08) 1487-1497
    CrossrefPubMedGoogle Scholar
  • 4 Castellino FJ, Ploplis VA. Structure and function of the plasminogen/plasmin system. Thromb Haemost 2005; 93 (04) 647-654
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 5 Rijken DC, Lijnen HR. New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost 2009; 7 (01) 4-13
    CrossrefPubMedGoogle Scholar
  • 6 Potempa J, Korzus E, Travis J. The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J Biol Chem 1994; 269 (23) 15957-15960
    CrossrefPubMedGoogle Scholar
  • 7 Silverman GA, Bird PI, Carrell RW. et al. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem 2001; 276 (36) 33293-33296
    CrossrefPubMedGoogle Scholar
  • 8 Carrell RW, Huntington JA, Mushunje A, Zhou A. The conformational basis of thrombosis. Thromb Haemost 2001; 86 (01) 14-22
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 9 Shieh BH, Potempa J, Travis J. The use of alpha 2-antiplasmin as a model for the demonstration of complex reversibility in serpins. J Biol Chem 1989; 264 (23) 13420-13423
    CrossrefPubMedGoogle Scholar
  • 10 Matheson NR, van Halbeek H, Travis J. Evidence for a tetrahedral intermediate complex during serpin-proteinase interactions. J Biol Chem 1991; 266 (21) 13489-13491
    CrossrefPubMedGoogle Scholar
  • 11 Ye S, Cech AL, Belmares R. et al. The structure of a Michaelis serpin-protease complex. Nat Struct Biol 2001; 8 (11) 979-983
    CrossrefPubMedGoogle Scholar
  • 12 Lindahl TL, Ohlsson PI, Wiman B. The mechanism of the reaction between human plasminogen-activator inhibitor 1 and tissue plasminogen activator. Biochem J 1990; 265 (01) 109-113
    CrossrefPubMedGoogle Scholar
  • 13 Fa M, Bergström F, Karolin J, Johansson LB, Ny T. Conformational studies of plasminogen activator inhibitor type 1 by fluorescence spectroscopy. Analysis of the reactive centre of inhibitory and substrate forms, and of their respective reactive-centre cleaved forms. Eur J Biochem 2000; 267 (12) 3729-3734
    CrossrefPubMedGoogle Scholar
  • 14 Lawrence DA, Ginsburg D, Day DE. et al. Serpin-protease complexes are trapped as stable acyl-enzyme intermediates. J Biol Chem 1995; 270 (43) 25309-25312
    CrossrefPubMedGoogle Scholar
  • 15 Wilczynska M, Fa M, Ohlsson PI, Ny T. The inhibition mechanism of serpins. Evidence that the mobile reactive center loop is cleaved in the native protease-inhibitor complex. J Biol Chem 1995; 270 (50) 29652-29655
    CrossrefPubMedGoogle Scholar
  • 16 Gong L, Liu M, Zeng T. et al. Crystal structure of the Michaelis complex between tissue-type plasminogen activator and plasminogen activators inhibitor-1. J Biol Chem 2015; 290 (43) 25795-25804
    CrossrefPubMedGoogle Scholar
  • 17 Thorsen S, Philips M. Isolation of tissue-type plasminogen activator-inhibitor complexes from human plasma. Evidence for a rapid plasminogen activator inhibitor. Biochim Biophys Acta 1984; 802 (01) 111-118
    CrossrefPubMedGoogle Scholar
  • 18 Sugiki M, Maruyama M, Yoshida E, Mihara H, Kamiguti AS, Theakston DG. Enhancement of plasma fibrinolysis in vitro by jararhagin, the main haemorrhagic metalloproteinase in Bothrops jararaca venom. Toxicon 1995; 33 (12) 1605-1617
    CrossrefPubMedGoogle Scholar
  • 19 Grailhea P, Bezeaudb A, Gaussema P. et al. Neutralization of plasminogen activator inhibitor-1 (PAI-1) by activated protein C is species-dependent. Fibrinolysis 1993; 7 (02) 123-133
    CrossrefPubMedGoogle Scholar
  • 20 Gaussem P, Grailhe P, Anglés-Cano E. Sodium dodecyl sulfate-induced dissociation of complexes between human tissue plasminogen activator and its specific inhibitor. J Biol Chem 1993; 268 (16) 12150-12155
    CrossrefPubMedGoogle Scholar
  • 21 Longstaff C, Gaffney PJ. Serpin-serine protease binding kinetics: alpha 2-antiplasmin as a model inhibitor. Biochemistry 1991; 30 (04) 979-986
    CrossrefPubMedGoogle Scholar
  • 22 Lawrence D, Strandberg L, Grundström T, Ny T. Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells. Eur J Biochem 1989; 186 (03) 523-533
    CrossrefPubMedGoogle Scholar
  • 23 Urano T, Strandberg L, Johansson LB, Ny T. A substrate-like form of plasminogen-activator-inhibitor type 1. Conversions between different forms by sodium dodecyl sulphate. Eur J Biochem 1992; 209 (03) 985-992
    CrossrefPubMedGoogle Scholar
  • 24 Kanemoto N, Goto Y, Hirosawa K. et al. Intravenous recombinant tissue-type plasminogen activator (rt-PA) and urokinase (UK) in patients with evolving myocardial infarction--a multicenter double-blind, randomized trial in Japan. Jpn Circ J 1991; 55 (03) 250-261
    CrossrefPubMedGoogle Scholar
  • 25 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227 (5259): 680-685
    CrossrefPubMedGoogle Scholar
  • 26 Kucherlapati R, Tepper R, Granelli-Piperno A, Reich E. Modulation and mapping of a human plasminogen activator by cell fusion. Cell 1978; 15 (04) 1331-1340
    CrossrefPubMedGoogle Scholar
  • 27 Lamba D, Bauer M, Huber R. et al. The 2.3 A crystal structure of the catalytic domain of recombinant two-chain human tissue-type plasminogen activator. J Mol Biol 1996; 258 (01) 117-135
    CrossrefPubMedGoogle Scholar
  • 28 Nukuna BN, Penn MS, Anderson VE, Hazen SL. Latency and substrate binding globally reduce solvent accessibility of plasminogen activator inhibitor type 1 (PAI-1). An adaptation of PAI-1 conformer crystal structures by hydrogen-deuterium exchange. J Biol Chem 2004; 279 (48) 50132-50141
    CrossrefPubMedGoogle Scholar
  • 29 Lin Z, Jiang L, Yuan C. et al. Structural basis for recognition of urokinase-type plasminogen activator by plasminogen activator inhibitor-1. J Biol Chem 2011; 286 (09) 7027-7032
    CrossrefPubMedGoogle Scholar
  • 30 Ibarra CA, Blouse GE, Christian TD, Shore JD. The contribution of the exosite residues of plasminogen activator inhibitor-1 to proteinase inhibition. J Biol Chem 2004; 279 (05) 3643-3650
    CrossrefPubMedGoogle Scholar
  • 31 Urano T, Sakakibara K, Rydzewski A, Urano S, Takada Y, Takada A. Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1. Thromb Haemost 1990; 63 (01) 82-86
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 32 Urano T, Sumiyoshi K, Pietraszek MH, Takada Y, Takada A. PAI-1 plays an important role in the expression of t-PA activity in the euglobulin clot lysis by controlling the concentration of free t-PA. Thromb Haemost 1991; 66 (04) 474-478
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 33 Urano T, Suzuki Y, Arakida M, Kanamori M, Takada A. The expression of exercise-induced tPA activity in blood is regulated by the basal level of PAI-1. Thromb Haemost 2001; 85 (04) 751-752
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 34 Keijer J, Linders M, Wegman JJ, Ehrlich HJ, Mertens K, Pannekoek H. On the target specificity of plasminogen activator inhibitor 1: the role of heparin, vitronectin, and the reactive site. Blood 1991; 78 (05) 1254-1261
    CrossrefPubMedGoogle Scholar
  • 35 Urano T, Nagai N, Matsuura M, Ihara H, Takada Y, Takada A. Human thrombin and calcium bound factor Xa significantly shorten tPA-induced fibrin clot lysis time via neutralization of plasminogen activator inhibitor type 1 activity. Thromb Haemost 1998; 80 (01) 161-166
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 36 Tomczyk M, Suzuki Y, Sano H, Brzoska T, Tanaka H, Urano T. Bidirectional functions of thrombin on fibrinolysis: Evidence of thrombin-dependent enhancement of fibrinolysis provided by spontaneous plasma clot lysis. Thromb Res 2016; 143: 28-33
    CrossrefPubMedGoogle Scholar
  • 37 Sakata Y, Curriden S, Lawrence D, Griffin JH, Loskutoff DJ. Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity. Proc Natl Acad Sci U S A 1985; 82 (04) 1121-1125
    CrossrefPubMedGoogle Scholar
  • 38 Suzuki Y, Mogami H, Ihara H, Urano T. Unique secretory dynamics of tissue plasminogen activator and its modulation by plasminogen activator inhibitor-1 in vascular endothelial cells. Blood 2009; 113 (02) 470-478
    CrossrefPubMedGoogle Scholar